ライフサイエンスコーパス: mouse mammary tumor virus

1 ranscription state of a GR-induced promoter (mouse mammary tumor virus).

2 uses efficient -1 ribosomal frameshifting in mouse mammary tumor virus.

3 against infections by viruses like HIV-1 and mouse mammary tumor virus.

4 simplex viruses, human papillomaviruses, and mouse mammary tumor viruses.

5 nt-6 (eIF3e), a frequent integration site of mouse mammary tumor viruses.

6 is one of the frequent integration sites for mouse mammary tumor viruses.

7 equence of nucleosome A of the 3'-LTR of the mouse mammary tumor virus (147 bp MMTV-A).

8 nce to an endogenous superantigen encoded by mouse mammary tumor virus 8 (Mtv-8) by either deletion o

9 mphoid periphery by superantigens encoded by mouse mammary tumor viruses-8 and -9 in an MHC class II-

10 e binding sites for two of these viruses-the mouse mammary tumor virus (a retrovirus) and Machupo vir

11 lex class I (MHC-I), C-type lectins, and the mouse mammary tumor virus and herpesvirus saimiri supera

12 lucocorticoid-inducible enhancer-promoter of mouse mammary tumor virus and introduced it into the lef

13 nous retrovirus K (HERV-K) is related to the mouse mammary tumor virus and is present in the genomes

14 ukemogenic virus (TBLV) is highly related to mouse mammary tumor virus but induces rapidly appearing

15 n primary mammary adenocarcinomas arising in mouse mammary tumor virus-c-erbB2 transgenic mice harbor

16 ed Akt activation and survival in transgenic mouse mammary tumor virus-c-Myc mouse mammary carcinoma

17 sion of tumors initiated by an overexpressed mouse mammary tumor virus-c-myc transgene, which on its

18 ng a T47D cell line stably integrated with a mouse mammary tumor virus-chloramphenicol acetyltransfer

19 y dexamethasone occurs via the disruption of mouse mammary tumor virus chromatin structure and the re

20 Finally, mammary tumors derived from mouse mammary tumor virus-CR-1 mice showed a dramatic re

21 ithelial cells isolated from Cav-1 null(-/-)/mouse mammary tumor virus-CR-1 transgenic animals showed

22 receptor type I (TGFbetaRI), either by using mouse mammary tumor virus-Cre mice or by delivering aden

23 The mouse mammary tumor virus-Cre-mediated excision of the f

24 hSwi-Snf appears to interact with naked mouse mammary tumor virus DNA somewhat differently than

25 Previously, mouse mammary tumor virus-driven polyoma middle T-antige

26 l-type breast adenomas with lung metastases [mouse mammary tumor virus-driven polyoma virus middle T

27 Mouse mammary tumor viruses encode superantigens that in

28 ction by a process that depends upon neither mouse mammary tumor virus-encoded superantigens nor MHC

29 virus middle T antigen, under control of the mouse mammary tumor virus enhancer/promoter, was used to

30 Mtv29 mouse mammary tumor virus env transcriptional activator

31 Compared with mouse mammary tumor virus-ErbB2 Ink4a/Arf(+/-) mice, mou

32 mmary tumor virus-ErbB2 Ink4a/Arf(+/-) mice, mouse mammary tumor virus-ErbB2 Ink4a/Arf(wt) mammary tu

33 In mouse mammary tumor virus-erbB2 mice treated with LGD106

34 suppresses ER-negative tumor development in mouse mammary tumor virus-erbB2 transgenic mice with min

35 the targets of tumorigenic transformation in mouse mammary tumor virus-erbB2 transgenic mice.

36 By the age of 4 months, 100% of female mouse mammary tumor virus-EZH2 virgin mice developed int

37 he few promoters amenable to analysis is the mouse mammary tumor virus gene regulatory sequence.

38 ivity equivalent to the entire 3'-end of the mouse mammary tumor virus genome, but further deletions

39 nized dexamethasone-induced activation of an mouse mammary tumor virus-glucocorticoid-response elemen

40 lity to target tumors overexpressing HER2 in mouse mammary tumor virus/HER2 allograft models.

41 -MS) to directly analyze protein profiles in mouse mammary tumor virus/HER2 transgenic mouse frozen t

42 ation of Wnt9b expression was detected in 29 mouse mammary tumor virus-induced tumors.

43 Aberrant activation of this gene by mouse mammary tumor virus insertion results in pregnancy

44 expression of cyclin D1 and wingless-related mouse mammary tumor virus integration site 10b (Wnt10b)

45 where they become inducible by wingless-type mouse mammary tumor virus integration site family member

46 he balance between mesenchymal Wingless-type Mouse Mammary Tumor Virus integration site family, membe

47 he timed secretion of Wingless-related MMTV (mouse mammary tumor virus) integration site 3 (WNT3) by

48 secrete the morphogen Wingless-related MMTV (mouse mammary tumor virus) integration site 3 (WNT3).

49 e roles of the canonical wingless-type MMTV (mouse mammary tumor virus) integration site family (WNT)

50 e that express Msx1 under the control of the mouse mammary tumor virus long terminal repeat (MMTV LTR

51 el cDNA was driven by the hormone-responsive mouse mammary tumor virus long terminal repeat (MMTV-LTR

52 on, whereas the sex-limited protein gene and mouse mammary tumor virus long terminal repeat do not.

53 ell-cell junctions, under the control of the mouse mammary tumor virus long terminal repeat promoter,

54 On both the WAP CoRE and the mouse mammary tumor virus long terminal repeat promoter,

55 e promoter (NFI-Ad), and 2) the more complex mouse mammary tumor virus long terminal repeat promoter.

56 by using the transcriptional activity of the mouse mammary tumor virus long terminal repeat.

57 N 89 beta-catenin) under the control of the mouse mammary tumor virus long terminal repeat.

58 f EZH2 to mammary epithelial cells using the mouse mammary tumor virus long terminal repeat.

59 using a neutralizing CSF-1R antibody in the mouse mammary tumor virus long-terminal region-driven po

60 ilizing a Cre transgene under control of the mouse mammary tumor virus-long terminal repeat (MMTV-LTR

61 ey acidic protein (WAP) gene promoter or the mouse mammary tumor virus-long terminal repeat (MMTV-LTR

62 ing the KI-GSK3beta under the control of the mouse mammary tumor virus-long terminal repeat develop m

63 control of the whey acidic protein (WAP) or mouse mammary tumor virus-long terminal repeat promoters

64 d copies of the steroid responsive MMTV-LTR (mouse mammary tumor virus-long terminal repeat), we show

65 nesis, transgenic mice were generated with a mouse mammary tumor virus-long terminal repeat-driven, c

66 Transgenic expression of this gene using a mouse mammary tumor virus LTR enhancer causes extensive

67 ng the known positions of nucleosomes on the mouse mammary tumor virus LTR, and additionally, we char

68 In these animals, mouse mammary tumor virus LTR-driven expression of the c

69 We show here that the wild-type mouse mammary tumor virus MMTV(C3H) persisted indefinite

70 Two other betaretroviruses, mouse mammary tumor virus (MMTV) and human endogenous re

71 In that regard, the mouse mammary tumor virus (MMTV) and its tumors of mice,

72 ant I/LnJ mice, which control infection with mouse mammary tumor virus (MMTV) and murine leukemia vir

73 wn that mouse APOBEC3 restricts infection by mouse mammary tumor virus (MMTV) and murine leukemia vir

74 ivation function on two different reporters, mouse mammary tumor virus (MMTV) and prostate-specific a

75 transactivate the glucocorticoid-responsive mouse mammary tumor virus (MMTV) and TAT3 promoters in a

76 to have 95% to 97% nucleotide homology with mouse mammary tumor virus (MMTV) and with retrovirus seq

77 /N x WAP-TGF-beta1 mating were injected with mouse mammary tumor virus (MMTV) at 8-10 weeks of age.

78 Integration of mouse mammary tumor virus (MMTV) at the common integrati

79 clinical trial, have suggested that a human mouse mammary tumor virus (MMTV) causes primary biliary

80 east cancer cells stably transfected with an mouse mammary tumor virus (MMTV) chloramphenicol acetylt

81 Mouse mammary tumor virus (MMTV) encodes a Rev-like prot

82 Mouse mammary tumor virus (MMTV) encodes a superantigen

83 Mouse mammary tumor virus (MMTV) encodes a superantigen

84 ressing VEGF(165)b, under the control of the mouse mammary tumor virus (MMTV) enhancer/promoter.

85 und in many oncogenic viruses, including the mouse mammary tumor virus (MMTV) envelope (Env).

86 he HIV TM-CT with sequences derived from the mouse mammary tumor virus (MMTV) envelope glycoprotein,

87 TBLV is highly related to mouse mammary tumor virus (MMTV) except that TBLV long t

88 Mouse mammary tumor virus (MMTV) expression is restricte

89 The mouse mammary tumor virus (MMTV) Gag protein directs the

90 Mouse mammary tumor virus (MMTV) has been classified as

91 The nucleocapsid protein (NC) from the mouse mammary tumor virus (MMTV) has been overexpressed

92 The mouse mammary tumor virus (MMTV) has been shown to integ

93 breast cancer with sequences similar to the mouse mammary tumor virus (MMTV) has been shown, but con

94 Mouse mammary tumor virus (MMTV) has frequently been use

95 The study of the mouse mammary tumor virus (MMTV) has provided important

96 Involvement of a virus similar to mouse mammary tumor virus (MMTV) in human breast cancer

97 e mouse APOBEC3 (mA3) restricts infection by mouse mammary tumor virus (MMTV) in its natural host.

98 viral pathogens, including HIV in humans and mouse mammary tumor virus (MMTV) in mice.

99 Mouse mammary tumor virus (MMTV) induces breast cancer w

100 iously, we showed that IFN-gamma elicited by mouse mammary tumor virus (MMTV) infection in I/LnJ mice

101 e strains showed that they were resistant to mouse mammary tumor virus (MMTV) infection.

102 Mouse mammary tumor virus (MMTV) is a betaretrovirus tha

103 Mouse mammary tumor virus (MMTV) is a complex murine ret

104 Mouse mammary tumor virus (MMTV) is a complex retrovirus

105 Mouse mammary tumor virus (MMTV) is a milk-transmitted b

106 Exogenous mouse mammary tumor virus (MMTV) is carried from the gut

107 Like other retroviruses, mouse mammary tumor virus (MMTV) is not efficiently elim

108 Mouse mammary tumor virus (MMTV) is transcribed at high

109 Exogenous mouse mammary tumor virus (MMTV) is transmitted via the

110 Because mouse mammary tumor virus (MMTV) is unable to infect Chi

111 We utilized the mouse mammary tumor virus (MMTV) long terminal repeat (L

112 liparous mice expressing Sim2s driven by the mouse mammary tumor virus (MMTV) long terminal repeat (L

113 he Cre recombinase gene under control of the mouse mammary tumor virus (MMTV) long terminal repeat or

114 rrepressor (SR) protein under control of the mouse mammary tumor virus (MMTV) long terminal repeat pr

115 to epithelial cells under the control of the mouse mammary tumor virus (MMTV) long terminal repeat pr

116 GFalpha), have been cloned downstream of the mouse mammary tumor virus (MMTV) long terminal repeat pr

117 iddle T (PyMT) oncogene under control of the mouse mammary tumor virus (MMTV) long-terminal repeat (M

118 biting 42% of the maximal effect of DEX in a mouse mammary tumor virus (MMTV) luciferase reporter tra

119 Expression of the mouse mammary tumor virus (MMTV) neu/erbB2 transgene in

120 tein for the activation of B cells by either mouse mammary tumor virus (MMTV) or murine leukemia viru

121 The Gag protein of the murine retrovirus mouse mammary tumor virus (MMTV) orchestrates the assemb

122 ong been known for shedding large amounts of mouse mammary tumor virus (MMTV) particles in milk and f

123 ssion of the glucocorticoid receptor-induced mouse mammary tumor virus (MMTV) promoter and of the Tat

124 Using the mouse mammary tumor virus (MMTV) promoter as a model, we

125 We have identified the mouse mammary tumor virus (MMTV) promoter as a target of

126 WI/SNF chromatin-remodeling complex, and the mouse mammary tumor virus (MMTV) promoter assembled in a

127 Activation of the mouse mammary tumor virus (MMTV) promoter by the glucoco

128 omatin structure using a tandem array of the mouse mammary tumor virus (MMTV) promoter driving a ras

129 The mouse mammary tumor virus (MMTV) promoter has been used

130 The mouse mammary tumor virus (MMTV) promoter has been used

131 RANK overexpression under the control of the mouse mammary tumor virus (MMTV) promoter in a transgeni

132 Our studies with the mouse mammary tumor virus (MMTV) promoter in chromatin s

133 otic stress response was investigated on the mouse mammary tumor virus (MMTV) promoter in different c

134 ion of activated human SMO (SmoM2) under the mouse mammary tumor virus (MMTV) promoter in transgenic

135 those domains required for activation of the mouse mammary tumor virus (MMTV) promoter in two distinc

136 Using the mouse mammary tumor virus (MMTV) promoter integrated int

137 The mouse mammary tumor virus (MMTV) promoter is a useful mo

138 is study examines the mechanism by which the mouse mammary tumor virus (MMTV) promoter is repressed b

139 Here, the basic features of mouse mammary tumor virus (MMTV) promoter nucleosomal ar

140 e dynamics of the interaction of PR with the mouse mammary tumor virus (MMTV) promoter reconstituted

141 Moreover, binding of SATB1 to the mouse mammary tumor virus (MMTV) promoter region dramati

142 Cdk2 fusion protein under the control of the mouse mammary tumor virus (MMTV) promoter results in mam

143 We used the mouse mammary tumor virus (MMTV) promoter to target expr

144 nsformation of the mammary gland we used the mouse mammary tumor virus (MMTV) promoter to target over

145 rticoid receptor-mediated stimulation of the mouse mammary tumor virus (MMTV) promoter, suggesting th

146 bition on steroid receptor activation of the mouse mammary tumor virus (MMTV) promoter, we found that

147 We used the mouse mammary tumor virus (MMTV) promoter, which adopts

148 GR)-mediated transcriptional activation of a mouse mammary tumor virus (MMTV) promoter-driven lucifer

149 In vivo, deletion of Ppm1d in mice bearing mouse mammary tumor virus (MMTV) promoter-driven oncogen

150 Mouse mammary tumor virus (MMTV) promoter-driven Ptn exp

151 p A receptor gene, tva, under control of the mouse mammary tumor virus (MMTV) promoter.

152 ated with activation of transcription at the mouse mammary tumor virus (MMTV) promoter.

153 iptional competence of the hormone inducible mouse mammary tumor virus (MMTV) promoter.

154 ulation by NFI proteins on the NFI-dependent mouse mammary tumor virus (MMTV) promoter.

155 ocation of six positioned nucleosomes in the mouse mammary tumor virus (MMTV) promoter.

156 he K303R mutant ERalpha under control of the mouse mammary tumor virus (MMTV) promoter.

157 P6 in mammary epithelial cells driven by the mouse mammary tumor virus (MMTV) promoter.

158 ne-dependent activation of stably integrated mouse mammary tumor virus (MMTV) promoters, and this coa

159 the structural features of isolated genomic mouse mammary tumor virus (MMTV) promoters.

160 WAP-p53(172H) in tumorigenesis, we performed mouse mammary tumor virus (MMTV) proviral mutagenesis.

161 The orally transmitted retrovirus mouse mammary tumor virus (MMTV) requires the intestinal

162 es Moloney murine leukemia virus (MMuLV) and mouse mammary tumor virus (MMTV) showed cell surface exp

163 The mouse mammary tumor virus (MMTV) superantigen induces T-

164 Mouse mammary tumor virus (MMTV) superantigens (vSAgs) c

165 B leukemogenic virus (TBLV) is a variant of mouse mammary tumor virus (MMTV) that causes T-cell lymp

166 Type B leukemogenic virus is a variant of mouse mammary tumor virus (MMTV) that causes thymic lymp

167 We previously have shown that CDP represses mouse mammary tumor virus (MMTV) transcription in tissue

168 Mouse mammary tumor virus (MMTV) transcription is highes

169 The beta retrovirus mouse mammary tumor virus (MMTV) uses transferrin recept

170 Type B leukemogenic virus (TBLV), a mouse mammary tumor virus (MMTV) variant, often induces

171 A novel common integration site for the mouse mammary tumor virus (MMTV) was identified (designa

172 tein (CDP) is a transcriptional repressor of mouse mammary tumor virus (MMTV), a betaretrovirus that

173 receptor alpha, c-myc, and those encoded by mouse mammary tumor virus (MMTV), a glucocorticoid-respo

174 This report shows for the first time that mouse mammary tumor virus (MMTV), a mammalian retrovirus

175 Mouse mammary tumor virus (MMTV), a well-characterized r

176 Many retroviruses, including mouse mammary tumor virus (MMTV), are transmitted most e

177 ludes Jaagsiekte sheep retrovirus (JSRV) and mouse mammary tumor virus (MMTV), as well as many endoge

178 MR structure of one such pseudoknot, that of mouse mammary tumor virus (MMTV), has revealed that it i

179 iency or mammary-specific deletion inhibited mouse mammary tumor virus (MMTV)- PyMT- and MMTV- Wnt1-d

180 We intercrossed mouse mammary tumor virus (MMTV)-c-neu transgenic mice w

181 n tumorigenesis as judged by findings with a mouse mammary tumor virus (MMTV)-c-rel transgenic mouse

182 Here we report that mouse mammary tumor virus (MMTV)-CDC37 transgenic mice d

183 gth Brca1 in mammary epithelial cells of the mouse mammary tumor virus (MMTV)-Cre Brca1 conditional e

184 of the first coding exon in the germ line of mouse mammary tumor virus (MMTV)-Cre transgenic mice.

185 The mouse mammary tumor virus (MMTV)-Cre-mediated, epithelia

186 Mouse mammary tumor virus (MMTV)-ErbB2 mice lacking PKCd

187 EGCG inhibited mouse mammary tumor virus (MMTV)-Her-2/neu NF639 cell gr

188 nase (PI3-K)-Akt kinase signaling pathway in mouse mammary tumor virus (MMTV)-Her-2/neu NF639 mouse b

189 ering the role of HER2/Neu in breast cancer, mouse mammary tumor virus (MMTV)-Her2/neu transgenic mic

190 ontext of HER-2 overexpression, we generated mouse mammary tumor virus (MMTV)-Hoxb7 transgenic mice,

191 Indeed, almost 90% of mouse mammary tumor virus (MMTV)-induced mammary tumors

192 wth of mammary carcinomas arising in situ in mouse mammary tumor virus (MMTV)-infected female C3H/HeN

193 splants and decreases mammary cancer risk in mouse mammary tumor virus (MMTV)-infected females even a

194 We previously reported a 660-bp mouse mammary tumor virus (MMTV)-like env gene sequence

195 The mouse mammary tumor virus (MMTV)-MT model of breast canc

196 In a mouse mammary tumor virus (MMTV)-MYC transgenic mouse mo

197 A total of 50 uniparous mouse mammary tumor virus (MMTV)-neu and 50 nuliparous M

198 ng growth factor beta (TGF-beta), we crossed mouse mammary tumor virus (MMTV)-Neu mice with MMTV-TGF-

199 ut PMCA2 inhibits the formation of tumors in mouse mammary tumor virus (MMTV)-Neu mice.

200 ited breast tumor formation in xenograft and mouse mammary tumor virus (MMTV)-neu mouse models in a m

201 increased angiogenic signaling in the NeuYD [mouse mammary tumor virus (MMTV)-Neu(ndl)-YD5] mammary t

202 When mouse mammary tumor virus (MMTV)-neu-induced tumor cells

203 R2-evoked breast tumorigenesis, we generated mouse mammary tumor virus (MMTV)-NeuNT transgenic mice l

204 nesis, Apc(Min/+) mice were crossed with the mouse mammary tumor virus (MMTV)-Polyoma virus middle T

205 versely, generation of mammary tumors in the mouse mammary tumor virus (MMTV)-polyoma virus middle T

206 thology after crossing the mutation into the mouse mammary tumor virus (MMTV)-polyoma virus middle T

207 e activator E2F transcription factors in the mouse mammary tumor virus (MMTV)-polyomavirus middle T o

208 Animals carrying both mouse mammary tumor virus (MMTV)-reverse tetracycline tr

209 r (FTI) L-744,832 causes tumor regression in mouse mammary tumor virus (MMTV)-v-Ha-ras transgenic mic

210 p53 cancer mutant knock-in (R175H) mice and mouse mammary tumor virus (MMTV)-Wnt-1 transgenic (mWnt-

211 Here, we have used mouse mammary tumor virus (MMTV)-Wnt1 transgenic mice, w

212 berrantly overexpressed in mammary tumors of mouse mammary tumor virus (MMTV)-Wnt1-transgenic mice an

213 eutralizing infection with a betaretrovirus, mouse mammary tumor virus (MMTV).

214 R-1 under the transcriptional control of the mouse mammary tumor virus (MMTV).

215 Sag and, subsequently, the life cycle of the mouse mammary tumor virus (MMTV).

216 s also known as a common integration site of mouse mammary tumor virus (MMTV).

217 doknots from simian retrovirus-1 (SRV-1) and mouse mammary tumor virus (MMTV).

218 78 markedly delays breast tumor formation in mouse mammary tumor virus (MMTV)/Neu + MMTV/transforming

219 otein was detected in breast carcinomas from mouse mammary tumor virus (MMTV)/neu mice.

220 gulated during lactation and is expressed in mouse mammary tumor virus (MMTV)/PyMT tumors.

221 ing the activated c-neu oncogene driven by a mouse mammary tumor virus (MMTV-neu) in vivo, we show th

222 using multiparous, ErbB2/Neu-overexpressing mouse mammary tumor virus (MMTV-Neu) mice have shown tha

223 However, the budding of mouse mammary tumor virus (MMTV; cytoplasmic assembly, u

224 terminal repeats (LTRs) of acquired somatic mouse mammary tumor viruses (MMTV) can activate juxtapos

225 The absence of endogenous mouse mammary tumor viruses (MMTVs) in the congenic mous

226 Mammary glands from MMTV (mouse mammary tumor virus)-neu/p27(+/-) mice exhibited a

227 Mouse mammary tumor virus-neu mice were bred with Id1-/-

228 nitiation and increases NOTCH1 activation in mouse mammary tumor virus-neu mice.

229 olution and accelerated tumor progression in mouse mammary tumor virus/neu transgenic mice by inhibit

230 the carboxyl-terminal (Cys(2)HisCys) ZBD of Mouse Mammary Tumor Virus nucleocapsid protein (MMTV NCp

231 or transcriptional activation from chromatin mouse mammary tumor virus or endogenous promoters in viv

232 In the mouse mammary tumor virus-Polyoma Middle T (MMTV-PyMT) m

233 aling once tumors have developed, we use the mouse mammary tumor virus-Polyoma Middle T (MMTV-PyMT),

234 In mouse mammary tumor virus-polyoma middle T (PyMT) breast

235 ancer development, we established cohorts of mouse mammary tumor virus-polyoma middle T (PyMT) PAR1(-

236 nic mouse model of breast cancer, MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen), wit

237 lac altered breast cancer development in the mouse mammary tumor virus-polyoma middle T-antigen model

238 /-) mice were generated and crossed with the Mouse Mammary Tumor Virus-Polyoma Middle T-Antigen mouse

239 g for this antitumor response, we engineered mouse mammary tumor virus-polyoma virus middle T antigen

240 c resulted in increased pAkt levels in total mouse mammary tumor virus-polyoma virus middle T antigen

241 sed mouse models of Kiss1r gene knockout and mouse mammary tumor virus-polyoma virus middle T antigen

242 ammary tumorigenesis, we generated wild-type mouse mammary tumor virus/polyoma middle-T (WT/PyMT) and

243 Collagen(-/-) mice in the background of the mouse mammary tumor virus/polyoma virus middle T oncogen

244 rom spontaneous mammary tumors that arose in mouse mammary tumor virus-polyomavirus (MMTV-PyV) Middle

245 d-type (WT) and AIB1(-/-) mice harboring the mouse mammary tumor virus-polyomavirus middle T (PyMT) t

246 om both implantable (4T1) and autochthonous (mouse mammary tumor virus-polyomavirus middle T Ag (MMTV

247 Tgfbr2MGKO mice were mated to the mouse mammary tumor virus-polyomavirus middle T antigen

248 et promoter, repressing transactivation from mouse mammary tumor virus, probasin, and prostate-specif

249 ssed phorbol-12-myristate-13-acetate-induced mouse mammary tumor virus promoter activity and phorbol

250 iption from an integrated steroid-responsive mouse mammary tumor virus promoter and also from an inte

251 moter and diminished activity on the complex mouse mammary tumor virus promoter compared with human G

252 ed progesterone-dependent PR activation of a mouse mammary tumor virus promoter in both prostate (PC-

253 Cortisol-dependent transactivation from the mouse mammary tumor virus promoter in cells lacking plas

254 fered in their ability to associate with the mouse mammary tumor virus promoter in organized chromati

255 us middle T antigen under the control of the mouse mammary tumor virus promoter in transgenic mice re

256 ice expressing MTA1 under the control of the mouse mammary tumor virus promoter long terminal repeat

257 n used to locate hSwi-Snf complexes bound to mouse mammary tumor virus promoter nucleosomal arrays, a

258 emodeling complex on individual, single-copy mouse mammary tumor virus promoter nucleosomal arrays.

259 (GR) and nuclear factor 1 (NF1) to bind the mouse mammary tumor virus promoter organized as regular

260 nd that LeTx repressed the activation of the mouse mammary tumor virus promoter related to overexpres

261 lucocorticoid receptor, to a tandem array of mouse mammary tumor virus promoter sites in live cells,

262 DAC inhibitors (KDACis) potently repress the mouse mammary tumor virus promoter through transcription

263 DeltaTR)-human MUC1 under the control of the mouse mammary tumor virus promoter to further examine th

264 G transgenic mice model under the control of mouse mammary tumor virus promoter was established and t

265 xpressing Polyoma middle T antigen under the mouse mammary tumor virus promoter were combined with mi

266 ining a unique C-->U substitution within the mouse mammary tumor virus promoter, one located within e

267 consisting of about 200 tandem repeats of a mouse mammary tumor virus promoter-driven ha-v-ras gene.

268 ous mammary cancers in mice transgenic for a mouse mammary tumor virus promoter-driven polyomavirus m

269 xpress ERalpha, were stably transfected with mouse mammary tumor virus promoter-luciferase (MMTV-LUC)

270 ction, as tested from a GR-responsive 330-bp mouse mammary tumor virus promoter-luciferase reporter c

271 A transcriptionally inert Mouse Mammary Tumor Virus promoter-region nucleosome (MM

272 dle T antigen (pMT) under the control of the mouse mammary tumor virus promoter.

273 ther CSF-1 or c-fms under the control of the mouse mammary tumor virus promoter.

274 F-beta type II receptor under control of the mouse mammary tumor virus promoter.

275 cell lines engineered to stably maintain the mouse mammary tumor virus promoter.

276 iption complexes on templates containing the mouse mammary tumor virus promoter.

277 inhibits hGRalpha-mediated activation of the mouse mammary tumor virus promoter.

278 ing a SnoN fragment under the control of the mouse mammary tumor virus promoter.

279 ssection of PR A-isoform interactions at the mouse mammary tumor virus promoter.

280 ms of cyclin E (T1) under the control of the mouse mammary tumor virus promoter.

281 jor transcription response elements from the mouse mammary tumor virus promoter.

282 of promoter nucleosomes (from yeast GAL10 or mouse mammary tumor virus promoters).

283 ol experiments were performed on a mutant of mouse mammary tumor virus pseudoknot (VPK), for which an

284 ess the stability of the folded structure of mouse mammary tumor virus pseudoknot in the presence of

285 tisense oligonucleotides (ASOs) in the MMTV (mouse mammary tumor virus)-PyMT mouse mammary carcinoma

286 With the use of a tandem array of mouse mammary tumor virus reporter elements and a form o

287 in these mice is conferred by an endogenous mouse mammary tumor virus superantigen (Mtv-7 sag) that

288 We show here that presentation of mouse mammary tumor virus superantigen does not require

289 a5(+) T cells are tolerized to an endogenous mouse mammary tumor virus superantigen either by deletio

290 Mouse mammary tumor virus superantigens (vSAGs) are noto

291 d a group of replication-competent exogenous mouse mammary tumor viruses that failed to induce mammar

292 dogenous nucleic acid sequence homology with mouse mammary tumor virus; therefore all viral insertion

293 e 9e and 15a are micromolar antagonists in a mouse mammary tumor virus transactivation assay.

294 AIB1(+/-), and AIB1(-/-) mice harboring the mouse mammary tumor virus/v-Ha-ras (ras) transgene that

295 Stimulation of the mouse mammary tumor virus with steroids results in the g

296 DKK1), an antagonist of the wingless-related mouse mammary tumor virus (WNT) signaling pathway, is on

297 S-15 and MDA-MB-231 breast cancer cells, and mouse mammary tumor virus-Wnt-1 mammary tumor-derived ce

298 se to tamoxifen in mammary tumors arising in mouse mammary tumor virus-Wnt-1 transgenic mice.

299 aling in the context of the well-established mouse mammary tumor virus-Wnt-1 transgenic mouse.

300 otent antitumor efficacy was shown using the mouse mammary tumor virus-Wnt1 tumor model under dosing